Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Summary
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Be willing and able to provide written informed consent/assent for the trial. * Be 18 years of age on day of signing informed consent. * Patients with non-bulky/non-bulky squamous cell carcinomas of the head and neck, with an indication for surgical therapy. 1. Surgically resectable disease - generally that is T1N1-N2B, T2-4N0-N2b stage are generally eligible (AJCC 7th), however exceptions can be made after approval by the PI for surgically appropriate cases. 2. If determined per tumor board that a low-volume/non-bulky tumor of another stage is appropriate for resec…
Interventions
- DrugPembrolizumab
Pembrolizumab is an investigational drug in this study
- DrugIO102-103
IO102-103 is an investigational drug in this study.
Locations (5)
- Sibley Memorial HospitalWashington D.C., District of Columbia
- Northwestern Memorial HospitalChicago, Illinois
- Johns Hopkins UniversityBaltimore, Maryland
- Providence Cancer InstitutePortland, Oregon
- Thomas Jefferson University HospitalPhiladelphia, Pennsylvania